抗免疫检查点分子抗体恢复肝细胞癌肿瘤浸润T细胞功能
该研究收集59例肝细胞癌(HCC)手术切除患者的肿瘤、癌旁肝组织及外周血样本,用流式细胞术检测抑制性受体表达,并在T细胞活化实验中研究阻断抗体的效应。发现HCC肿瘤浸润CD8+和CD4+ T细胞上PD-1、TIM3、LAG3、CTLA4表达显著高于对照组织和血液,抗PD-L1、TIM3或LAG3抗体可恢复T细胞对肿瘤抗原的应答,联合抗体具有叠加效应。
要点
- HCC肿瘤浸润CD8+和CD4+ T细胞上PD-1、TIM3、LAG3、CTLA4表达显著高于癌旁肝组织和外周血。
- 肿瘤相关抗原(TAA)特异性CD8+肿瘤浸润淋巴细胞(TIL)上PD-1、TIM3、LAG3表达高于其他CD8+ TIL。
- 抗PD-L1、TIM3或LAG3抗体可增加CD8+和CD4+ TIL的增殖和细胞因子产生,联合抗体具有叠加效应。
核心结论
- 免疫检查点抑制分子PD-1、TIM3、LAG3在人HCC组织来源的TAA特异性T细胞上上调,抗PD-L1、TIM3或LAG3抗体可恢复HCC来源T细胞对肿瘤抗原的应答,联合抗体具有叠加效应。
- 阻断PD-L1、TIM3、LAG3的策略可能被开发用于原发性肝癌的治疗。
研究设计与样本
- 研究收集2013年11月至2017年5月期间接受手术切除的59例HCC患者的HCC样本、无肿瘤肝组织(对照组织)和外周血样本。
- 分离肿瘤浸润淋巴细胞(TIL)和肝内淋巴细胞,用流式细胞术定量CD8+和CD4+ T细胞上PD-1、甲型肝炎病毒细胞受体2(TIM3)、淋巴细胞活化基因3(LAG3)和CTLA4的表达,并在T细胞活化实验中研究阻断这些通路的抗体的效应。
主要发现
- HCC组织分离的CD8+和CD4+ T细胞上PD-1、TIM3、LAG3和CTLA4表达显著高于对照组织或血液。
- HCC肿瘤中的树突状细胞、单核细胞和B细胞表达这些受体的配体。
- TAA特异性CD8+ TIL上PD-1、TIM3和LAG3表达高于其他CD8+ TIL。
- 表达这些抑制性受体的CD8+和CD4+ TIL与不表达这些受体的TIL相比,活化标志物水平更高,但颗粒酶B和效应细胞因子水平相似或降低。
- 抗CD274(PD-配体1[PD-L1])、TIM3或LAG3抗体增加CD8+和CD4+ TIL在聚克隆抗原或TAA刺激下的增殖和细胞因子产生;抗PD-L1抗体与抗TIM3、LAG3或CTLA4抗体联合进一步增加TIL功能。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Ligand binding to inhibitory receptors on immune cells, such as programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4), down-regulates the T-cell-mediated immune response (called immune checkpoints). Antibodies that block these receptors increase antitumor immunity in patients with melanoma, non-small-cell lung cancer, and renal cell cancer. Tumor-infiltrating CD4+ and CD8+ T cells in patients with hepatocellular carcinoma (HCC) have been found to be functionally compromised. We analyzed HCC samples from patients to determine if these inhibitory pathways prevent T-cell responses in HCCs and to find ways to restore their antitumor functions. METHODS: We collected HCC samples from 59 patients who underwent surgical resection from November 2013 through May 2017, along with tumor-free liver tissues (control tissues) and peripheral blood samples. We isolated tumor-infiltrating lymphocytes (TIL) and intra-hepatic lymphocytes. We used flow cytometry to quantify expression of the inhibitory receptors PD-1, hepatitis A virus cellular receptor 2 (TIM3), lymphocyte activating 3 (LAG3), and CTLA4 on CD8+ and CD4+ T cells from tumor, control tissue, and blood; we studied the effects of antibodies that block these pathways in T-cell activation assays. RESULTS: Expression of PD-1, TIM3, LAG3, and CTLA4 was significantly higher on CD8+ and CD4+ T cells isolated from HCC tissue than control tissue or blood. Dendritic cells, monocytes, and B cells in HCC tumors expressed ligands for these receptors. Expression of PD-1, TIM3, and LAG3 was higher on tumor-associated antigen (TAA)-specific CD8+ TIL, compared with other CD8+ TIL. Compared with TIL that did not express these inhibitory receptors, CD8+ and CD4+ TIL that did express these receptors had higher levels of markers of activation, but similar or decreased levels of granzyme B and effector cytokines. Antibodies against CD274 (PD-ligand1 [PD-L1]), TIM3, or LAG3 increased proliferation of CD8+ and CD4+ TIL and cytokine production in response to stimulation with polyclonal antigens or TAA. Importantly, combining antibody against PD-L1 with antibodies against TIM3, LAG3, or CTLA4 further increased TIL functions. CONCLUSIONS: The immune checkpoint inhibitory molecules PD-1, TIM3, and LAG3 are up-regulated on TAA-specific T cells isolated from human HCC tissues, compared with T cells from tumor-free liver tissues or blood. Antibodies against PD-L1, TIM3, or LAG3 restore responses of HCC-derived T cells to tumor antigens, and combinations of the antibodies have additive effects. Strategies to block PD-L1, TIM3, and LAG3 might be developed for treatment of primary liver cancer.
引用
- Zhou G, Sprengers D, Boor PPC, et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology. 2017. PMID: 28648905. doi:10.1053/j.gastro.2017.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。